JO3442B1 - مضادات ذات نوع فرعي من مستقبل سوماتوستاتين 5 (sstr5) - Google Patents

مضادات ذات نوع فرعي من مستقبل سوماتوستاتين 5 (sstr5)

Info

Publication number
JO3442B1
JO3442B1 JOP/2014/0283A JOP20140283A JO3442B1 JO 3442 B1 JO3442 B1 JO 3442B1 JO P20140283 A JOP20140283 A JO P20140283A JO 3442 B1 JO3442 B1 JO 3442B1
Authority
JO
Jordan
Prior art keywords
sstr5
antagonists
compound
receptor subtype
somatostatin receptor
Prior art date
Application number
JOP/2014/0283A
Other languages
English (en)
Inventor
Shizuo Kasai
Hideki Hirose
Asato Kina
Tohru Yamashita
Yoichi Nishikawa
Takeshi Yamasaki
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Application granted granted Critical
Publication of JO3442B1 publication Critical patent/JO3442B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

<strong>يتعلق الاختراع الحالي بتوفير مركب له فعل مضاد </strong><span dir="LTR">SSTR5</span><strong> واستخدام المركب كدواء. على وجه التحديد، مركب يتم التعبير عنه بواسطة الصيغة التالية:</strong> <span dir="LTR"><img alt="??????? PT38-0003 ?????? 2013-20982620131007----00850075251302101257??20131007102827201310071027595150__________PT_84" src="file:///C:/Users/Darwish.Q/AppData/Local/Temp/msohtmlclip1/01/clip_image002.png" /></span> <strong>حيث يكون كل رمز كما تم التحديد في هذه الوثيقة،</strong> <strong> أو ملح منه، ويتم توفير دواء يشتمل على المركب أو ملح منه، واستخدام المركب أو ملح منه كعامل للوقاية من أو علاج مرض السكر. </strong>
JOP/2014/0283A 2013-10-07 2014-10-02 مضادات ذات نوع فرعي من مستقبل سوماتوستاتين 5 (sstr5) JO3442B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2013209826 2013-10-07

Publications (1)

Publication Number Publication Date
JO3442B1 true JO3442B1 (ar) 2019-10-20

Family

ID=51842719

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2014/0283A JO3442B1 (ar) 2013-10-07 2014-10-02 مضادات ذات نوع فرعي من مستقبل سوماتوستاتين 5 (sstr5)

Country Status (23)

Country Link
US (2) US9353108B2 (ar)
EP (1) EP3055309B1 (ar)
JP (1) JP6411520B2 (ar)
CN (1) CN105612158B (ar)
AR (1) AR097932A1 (ar)
BR (1) BR112016007620B1 (ar)
CA (1) CA2926544C (ar)
CY (1) CY1121163T1 (ar)
DK (1) DK3055309T3 (ar)
ES (1) ES2687102T3 (ar)
HR (1) HRP20181372T1 (ar)
HU (1) HUE039386T2 (ar)
JO (1) JO3442B1 (ar)
LT (1) LT3055309T (ar)
PL (1) PL3055309T3 (ar)
PT (1) PT3055309T (ar)
RS (1) RS57743B1 (ar)
RU (1) RU2671958C2 (ar)
SI (1) SI3055309T1 (ar)
TR (1) TR201810506T4 (ar)
TW (1) TWI648276B (ar)
UY (1) UY35774A (ar)
WO (1) WO2015052910A1 (ar)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9605000B2 (en) * 2013-03-14 2017-03-28 Takeda Pharmaceutical Company Limited Spiro azetidine isoxazole derivatives and their use as SSTR antagonists
EP3227282B1 (en) * 2014-12-02 2019-04-03 F.Hoffmann-La Roche Ag Novel piperidine derivatives
TW201712012A (zh) 2015-06-16 2017-04-01 美國禮來大藥廠 ２－側氧基－１，３，８－三氮雜螺［４．５］癸－３－基羧酸衍生物
BR112022006546A2 (pt) 2019-10-07 2022-08-30 Kallyope Inc Agonistas de gpr119
TW202207929A (zh) * 2020-05-13 2022-03-01 日商思可海雅藥品股份有限公司 膽道系疾病的診斷輔助、預防或治療劑
AU2021275038A1 (en) 2020-05-19 2022-12-22 Kallyope, Inc. AMPK activators
CN116390925A (zh) 2020-06-26 2023-07-04 卡尔优普公司 Ampk活化剂
CN116354961A (zh) * 2021-12-27 2023-06-30 中国科学院上海药物研究所 生长抑素受体5拮抗剂及其药物组合物及用途

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5356906A (en) 1989-10-27 1994-10-18 The Du Pont Merck Pharmaceutical Company (N-phthalimidoalkyl) piperidines useful as treatments for psychosis
EP0862562B1 (en) 1995-09-13 2001-07-04 Takeda Chemical Industries, Ltd. Benzoxazepine compounds, their production and use as lipid lowering agents
AU2001269531A1 (en) 2000-07-17 2002-01-30 Takeda Chemical Industries Ltd. Sulfone derivatives, process for their production and use thereof
US7071207B2 (en) 2001-09-24 2006-07-04 Bayer Pharmaceuticals Corporation Preparation and use of 1,5,6,7-tetrahydropyrrolo[3,2-c]pyridine derivatives for treatment of obesity
MXPA04002035A (es) * 2001-09-26 2004-06-07 Bayer Pharmaceuticals Corp Derivados de 1, 8-naftiridina y su uso para el tratamiento de la diabetes y trastornos relacionados.
TW200302225A (en) 2001-12-04 2003-08-01 Bristol Myers Squibb Co Substituted amino methyl factor Xa inhibitors
MXPA05004505A (es) 2002-11-01 2005-07-26 Takeda Pharmaceutical Agente para prevenir o tratar la neuropatia.
EP1559422B1 (en) 2002-11-08 2014-04-30 Takeda Pharmaceutical Company Limited Receptor function controlling agent
CA2507026A1 (en) 2002-11-22 2004-06-10 Takeda Pharmaceutical Company Limited Imidazole derivatives, their production and use
AU2004220225B2 (en) 2003-03-14 2010-06-17 Ono Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient
EP1630152A4 (en) 2003-05-30 2009-09-23 Takeda Pharmaceutical CONNECTION WITH CONDENSED RING
EP1669352A4 (en) 2003-09-30 2008-12-17 Takeda Pharmaceutical THIAZOLINE DERIVATIVE AND ITS USE
JP2007513082A (ja) 2003-11-10 2007-05-24 シエーリング アクチエンゲゼルシャフト Ｃｃｒ−５アンタゴニストとして有用なベンジルエーテルアミン化合物
US7820673B2 (en) 2003-12-17 2010-10-26 Takeda Pharmaceutical Company Limited Urea derivative, process for producing the same, and use
RU2006126978A (ru) 2003-12-25 2008-01-27 Такеда Фармасьютикал Компани Лимитед (Jp) Производные 3-(4-бензилоксифенил)пропановой кислоты
JP4855777B2 (ja) 2003-12-26 2012-01-18 武田薬品工業株式会社 フェニルプロパン酸誘導体
JP4875978B2 (ja) 2004-03-15 2012-02-15 武田薬品工業株式会社 アミノフェニルプロパン酸誘導体
EP2253315A1 (en) 2004-03-30 2010-11-24 Takeda Pharmaceutical Company Limited Alkoxyphenylpropanoic acid derivatives
TWI396686B (zh) 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
EP1873144B1 (en) 2005-04-20 2014-07-23 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
EP1911738A4 (en) 2005-07-29 2009-12-16 Takeda Pharmaceutical PHENOXYALKANSÄUREVERBINDUNG
WO2007013689A1 (ja) 2005-07-29 2007-02-01 Takeda Pharmaceutical Company Limited シクロプロパンカルボン酸化合物
AU2006277231A1 (en) 2005-08-10 2007-02-15 Takeda Pharmaceutical Company Limited Therapeutic agent for diabetes
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
AU2007265966B2 (en) 2006-06-27 2012-05-17 Takeda Pharmaceutical Company Limited Fused cyclic compounds
JP2010500391A (ja) 2006-08-15 2010-01-07 エフ．ホフマン−ラ ロシュ アーゲー フェニル、ピリジン及びキノリン誘導体
US8492405B2 (en) 2006-10-18 2013-07-23 Takeda Pharmaceutical Company Limited Glucokinase-activating fused heterocyclic compounds and methods of treating diabetes and obesity
NZ576570A (en) 2006-10-19 2010-11-26 Takeda Pharmaceutical 7-sulfonylamino-2-thiazol and 2-thiadiazol -indole compounds
JPWO2008093639A1 (ja) 2007-01-29 2010-05-20 武田薬品工業株式会社 ピラゾール化合物
EA200970746A1 (ru) 2007-02-09 2010-02-26 Такеда Фармасьютикал Компани Лимитед Конденсированные циклические соединения в качестве частичных агонистов ppar-гамма
US7862825B2 (en) 2007-02-21 2011-01-04 Mladen Vranic Method of controlling tight blood glucose by somatostatin receptor antagonists
US7799806B2 (en) * 2007-04-04 2010-09-21 Hoffmann-La Roche Inc. Substituted n-benzyl piperidines as somatostatin receptor modulators
WO2008136428A1 (ja) 2007-04-27 2008-11-13 Takeda Pharmaceutical Company Limited 含窒素５員複素環化合物
US20080306116A1 (en) 2007-06-08 2008-12-11 Christ Andreas D Aryloxazole, aryloxadiazole and benzimidazole derivatives
EP2157859A4 (en) 2007-06-19 2011-01-12 Takeda Pharmaceutical INDAZOL COMPOUNDS FOR THE ACTIVATION OF GLUCCOKINASE
TW200918062A (en) * 2007-09-12 2009-05-01 Wyeth Corp Azacyclylisoquinolinone and-isoindolinone derivatives as histamine-3 antagonists
AU2010245889A1 (en) 2009-05-07 2011-11-03 Merck Sharp & Dohme Corp. Substituted spirocyclic amines useful as antidiabetic compounds
EP2605658B1 (en) 2010-08-18 2016-03-23 Merck Sharp & Dohme Corp. Spiroxazolidinone compounds
WO2012069917A1 (en) 2010-11-26 2012-05-31 Lupin Limited Bicyclic gpr119 modulators
US9605000B2 (en) 2013-03-14 2017-03-28 Takeda Pharmaceutical Company Limited Spiro azetidine isoxazole derivatives and their use as SSTR antagonists
PT3063139T (pt) 2013-10-29 2019-02-22 Takeda Pharmaceuticals Co Composto heterocíclico

Also Published As

Publication number Publication date
EP3055309B1 (en) 2018-06-13
RU2016117732A (ru) 2017-11-15
US9353108B2 (en) 2016-05-31
EP3055309A1 (en) 2016-08-17
TWI648276B (zh) 2019-01-21
BR112016007620A2 (pt) 2017-08-01
TR201810506T4 (tr) 2018-08-27
WO2015052910A1 (en) 2015-04-16
BR112016007620B1 (pt) 2020-05-26
PT3055309T (pt) 2018-10-01
CA2926544C (en) 2021-07-06
US20160237087A1 (en) 2016-08-18
AR097932A1 (es) 2016-04-20
SI3055309T1 (sl) 2018-10-30
JP6411520B2 (ja) 2018-10-24
LT3055309T (lt) 2018-08-27
JP2016531950A (ja) 2016-10-13
UY35774A (es) 2015-05-29
CA2926544A1 (en) 2015-04-16
HUE039386T2 (hu) 2018-12-28
DK3055309T3 (en) 2018-08-27
HRP20181372T1 (hr) 2018-10-19
TW201536784A (zh) 2015-10-01
CN105612158B (zh) 2017-06-30
RS57743B1 (sr) 2018-12-31
US9751878B2 (en) 2017-09-05
PL3055309T3 (pl) 2018-10-31
CN105612158A (zh) 2016-05-25
CY1121163T1 (el) 2020-05-29
ES2687102T3 (es) 2018-10-23
US20150099777A1 (en) 2015-04-09
RU2671958C2 (ru) 2018-11-08

Similar Documents

Publication Publication Date Title
JO3442B1 (ar) مضادات ذات نوع فرعي من مستقبل سوماتوستاتين 5 (sstr5)
PH12016501614A1 (en) Heterocyclic compound
PH12016501582A1 (en) Fused heterocyclic compound
MX2019010531A (es) Compuesto peptidico.
PH12015502031A1 (en) Tetrahydropyrrolothiazine compounds
PH12014502857A1 (en) Analogs of glucagon exhibiting gip receptor activity
MX2014015558A (es) Analogos de glucagon que exhiben actividad del receptor gip.
NZ629025A (en) Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists
PH12015501363B1 (en) Chloro-pyrazine carboxamide derivatives with epithelial sodium channel blocking activity
MX2016004088A (es) Compuesto que tiene actividad agonistica del receptor de somatostatina y uso farmaceutico del mismo.
EA201692433A1 (ru) Соединения ppar для применения при лечении фиброзных заболеваний
AR128158A2 (es) Compuesto heterocíclico
EA201591645A1 (ru) Hантагонисты, имеющие феноксипиперидиновое ядро в структуре
EA201370149A1 (ru) Антагонисты рецептора
NZ731607A (en) Dihydropyrimidin-2- one compounds and medical use thereof
TN2017000097A1 (en) Heterocyclic compound
MX2017006110A (es) Carboxamidas de quinolina para usarse en el tratamiento de leucemia.
PH12015502703A1 (en) Pharmaceutical compositions
NZ715554A (en) Method of treating hypertrophic cardiomyopathy
UA86566U (en) N-hydroxyhomoazaadamantanone and dioxomolybdenum complex thereof
IN2013MU02610A (ar)
UA90817U (uk) Сполука 1,1-діетилкарбокси-2-трифторметил-2-(5&#39;-бромуридил-1&#39;-)етилен з потенційними фізіологічними властивостями
UA87694U (uk) Сполука 4,5,6,7-тетрагідро-3н-2-n-(пара-метоксифенациламіно)-азепіну гідрохлорид з потенційними фізіологічними властивостями